Istituto Biochimico Italiano (IBI)
Istituto Biochimico Italiano (Ibi) founded by Prof. Giovanni Lorenzini, is a pharmaceutical company of great scientific tradition in the Italian market from more than 90 years, with research objectives, innovation and production. Besides the historical firm tradition, the new technologies applied in the production and careful attention, make Ibi synonymous with reliability and quality assurance in the countries where the Company is present.
Ibi is dedicating its activity to the development of new therapeutic applications to offer alternative solutions to doctors and patients and is now well established in Italy, Europe, Asia, Australia and the US.
With its 45mio vials capacity of filling in asepsis, Ibi offers services and cutting-edge technology which put it among the top 10 Italian companies in contract manufacturing of different molecules. Ibi exports most of its products, equivalent to 2/3 of the production and is one of the few companies outside American territory, to have obtained FDA approval for the production of sterile penicillins for the US market.
Via Fossignano 2
Loredana has thirty years of experience in Pharmaceutical Research & Development. In 1987, she graduated in Chemistry at the University of Rome. Since 2006, she has been the Director of Research and Development of IBI. Today, her team deals with all the activities related to internal R&D projects and Contract Development and Manufacturing, from laboratory trials to GMP production of Investigational Medicinal Products. She is also responsible of the Biotechnology Department, where fermentation and purification processes, from mammalian cells, are developed.
Chiara graduated in Chemistry and Pharmaceutical Technology. She has been working in R&D laboratories of IBI since 2011. She has experience in formulation development and analytical validation. She has already taken part to national projects about nanoparticles formulations.